Tumour cells with BRAF (most frequently BRAFV600E) or KRAS mutations are addicted to MEK1/2 (MAPK or ERK Kinase)–ERK1/2 (extracellular signal-regulated kinase) signalling for their proliferation, survival and other malignant properties. This evidence concerns the gene MAPK3 and neoplasm.